

Ennio Giulio Favalli

List of Publications by Citations

Source: <https://exaly.com/author-pdf/7885309/ennio-giulio-favalli-publications-by-citations.pdf>

Version: 2024-04-23

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

110
papers

3,351
citations

32
h-index

54
g-index

140
ext. papers

4,031
ext. citations

5.8
avg. IF

6.13
L-index

#	Paper	IF	Citations
110	COVID-19 infection and rheumatoid arthritis: Faraway, so close!. <i>Autoimmunity Reviews</i> , 2020 , 19, 102523	33.6	241
109	Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: an approach to a personalized medicine. <i>Arthritis Care and Research</i> , 2013 , 65, 94-100	4.7	137
108	Baricitinib for COVID-19: a suitable treatment?. <i>Lancet Infectious Diseases</i> , 2020 , 20, 1012-1013	25.5	137
107	Serious infections during anti-TNF α treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 266-73	13.6	134
106	Long-term anti-TNF therapy and the risk of serious infections in a cohort of patients with rheumatoid arthritis: comparison of adalimumab, etanercept and infliximab in the GISEA registry. <i>Autoimmunity Reviews</i> , 2012 , 12, 225-9	13.6	125
105	TNF-alpha antagonist survival rate in a cohort of rheumatoid arthritis patients observed under conditions of standard clinical practice. <i>Annals of the New York Academy of Sciences</i> , 2009 , 1173, 837-46	6.5	110
104	Treatment of rheumatoid arthritis with anti-TNF-alpha agents: a reappraisal. <i>Autoimmunity Reviews</i> , 2009 , 8, 274-80	13.6	89
103	Inflammatory and prothrombotic biomarkers in patients with rheumatoid arthritis: effects of tumor necrosis factor-alpha blockade. <i>Journal of Autoimmunity</i> , 2008 , 31, 175-9	15.5	87
102	International consensus: What else can we do to improve diagnosis and therapeutic strategies in patients affected by autoimmune rheumatic diseases (rheumatoid arthritis, spondyloarthritis, systemic sclerosis, systemic lupus erythematosus, antiphospholipid syndrome and Sjogren's syndrome)? <i>Thrombosis and Haemostasis</i> , 2017 , 117, 101-10	13.6	84
101	Damage progression in rheumatoid arthritis: the role of biologic agents. <i>Arthritis Research and Therapy</i> , 2012 , 14,	5.7	78
100	Newly identified antiatherosclerotic activity of methotrexate and adalimumab: complementary effects on lipoprotein function and macrophage cholesterol metabolism. <i>Arthritis and Rheumatology</i> , 2015 , 67, 1155-64	9.5	76
99	What is the true incidence of COVID-19 in patients with rheumatic diseases?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e18	2.4	73
98	Tumour necrosis factor antagonist therapy and cancer development: analysis of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010 , 9, 175-80	13.6	71
97	Tocilizumab in the treatment of rheumatoid arthritis: an evidence-based review and patient selection. <i>Drug Design, Development and Therapy</i> , 2019 , 13, 57-70	4.4	71
96	Incidence of COVID-19 in Patients With Rheumatic Diseases Treated With Targeted Immunosuppressive Drugs: What Can We Learn From Observational Data?. <i>Arthritis and Rheumatology</i> , 2020 , 72, 1600-1606	9.5	68
95	Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. <i>Lupus</i> , 2002 , 11, 753-5	2.6	67
94	Profile of sarilumab and its potential in the treatment of rheumatoid arthritis. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1593-1603	4.4	64

93	Patient preferences in the choice of anti-TNF therapies in rheumatoid arthritis. Results from a questionnaire survey (RIVIERA study). <i>Rheumatology</i> , 2010 , 49, 289-94	3.9	63
92	Survival on treatment with second-line biologic therapy: a cohort study comparing cycling and swap strategies. <i>Rheumatology</i> , 2014 , 53, 1664-8	3.9	60
91	Twelve-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Rheumatoid Arthritis: Real-Life Data From a Local Registry. <i>Arthritis Care and Research</i> , 2016 , 68, 432-9	4.7	57
90	Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an "anchor" drug?. <i>Autoimmunity Reviews</i> , 2014 , 13, 1102-8	13.6	55
89	Incidence and Clinical Course of COVID-19 in Patients with Connective Tissue Diseases: A Descriptive Observational Analysis. <i>Journal of Rheumatology</i> , 2020 , 47, 1296	4.1	54
88	Second-line biologic therapy optimization in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. <i>Seminars in Arthritis and Rheumatism</i> , 2017 , 47, 183-192	5.3	53
87	Efficacy and safety of anti-tumour necrosis factor in elderly patients with rheumatoid arthritis: an observational study. <i>Clinical Reviews in Allergy and Immunology</i> , 2010 , 38, 90-6	12.3	52
86	The 12-item Psoriatic Arthritis Impact of Disease Questionnaire: Construct Validity, Reliability, and Interpretability in a Clinical Setting. <i>Journal of Rheumatology</i> , 2017 , 44, 279-285	4.1	51
85	The management of first-line biologic therapy failures in rheumatoid arthritis: Current practice and future perspectives. <i>Autoimmunity Reviews</i> , 2017 , 16, 1185-1195	13.6	51
84	Sex and Management of Rheumatoid Arthritis. <i>Clinical Reviews in Allergy and Immunology</i> , 2019 , 56, 333-345	3.5	49
83	Predicting response to anti-TNF treatment in rheumatoid arthritis patients. <i>Autoimmunity Reviews</i> , 2009 , 8, 431-7	13.6	47
82	Anti-CarP antibodies as promising marker to measure joint damage and disease activity in patients with rheumatoid arthritis. <i>Immunologic Research</i> , 2015 , 61, 24-30	4.3	42
81	Tailored first-line biologic therapy in patients with rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis. <i>Seminars in Arthritis and Rheumatism</i> , 2016 , 45, 519-32	5.3	41
80	Switching TNF-alpha antagonists in rheumatoid arthritis: the experience of the LORHEN registry. <i>Autoimmunity Reviews</i> , 2010 , 9, 465-9	13.6	35
79	Anti-TNFalpha therapy in a cohort of rheumatoid arthritis patients: clinical outcomes. <i>Autoimmunity Reviews</i> , 2009 , 8, 260-5	13.6	32
78	Targeting Granulocyte-Monocyte Colony-Stimulating Factor Signaling in Rheumatoid Arthritis: Future Prospects. <i>Drugs</i> , 2019 , 79, 1741-1755	12.1	31
77	Understanding the Role of Interleukin-6 (IL-6) in the Joint and Beyond: A Comprehensive Review of IL-6 Inhibition for the Management of Rheumatoid Arthritis. <i>Rheumatology and Therapy</i> , 2020 , 7, 473-516	4.4	30
76	Recommendations for the use of biologic therapy in rheumatoid arthritis: update from the Italian Society for Rheumatology II. Safety. <i>Clinical and Experimental Rheumatology</i> , 2011 , 29, S15-27	2.2	30

75	Ten-year drug survival of anti-TNF agents in the treatment of inflammatory arthritides. <i>Drug Development Research</i> , 2014 , 75 Suppl 1, S38-41	5.1	28
74	Upadacitinib and filgotinib: the role of JAK1 selective inhibition in the treatment of rheumatoid arthritis. <i>Drugs in Context</i> , 2019 , 8, 212595	5.2	28
73	Real-world experience of tocilizumab in rheumatoid arthritis: sub-analysis of data from the Italian biologics Register GISEA. <i>Clinical Rheumatology</i> , 2018 , 37, 315-321	3.9	27
72	Are patients with systemic lupus erythematosus at increased risk for COVID-19?. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e25	2.4	27
71	Biomarkers in psoriatic arthritis: a systematic literature review. <i>Expert Review of Clinical Immunology</i> , 2016 , 12, 651-60	5.1	26
70	COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country. <i>Pediatric Rheumatology</i> , 2020 , 18, 35	3.5	26
69	Real-life 10-year retention rate of first-line anti-TNF drugs for inflammatory arthritides in adult- and juvenile-onset populations: similarities and differences. <i>Clinical Rheumatology</i> , 2017 , 36, 1747-1755	3.9	23
68	Eight-Year Retention Rate of First-Line Tumor Necrosis Factor Inhibitors in Spondyloarthritis: A Multicenter Retrospective Analysis. <i>Arthritis Care and Research</i> , 2017 , 69, 867-874	4.7	23
67	Biologic therapy and spinal radiographic progression in patients with axial spondyloarthritis: A structured literature review. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2020 , 12, 1759720X20906040	3.8	21
66	Anti-tumor necrosis factor alpha switching in rheumatoid arthritis and juvenile chronic arthritis. <i>Arthritis and Rheumatism</i> , 2004 , 51, 301-2		21
65	Novel mechanisms of action of the biologicals in rheumatic diseases. <i>Clinical Reviews in Allergy and Immunology</i> , 2014 , 47, 6-16	12.3	20
64	Mavrilimumab: a unique insight and update on the current status in the treatment of rheumatoid arthritis. <i>Expert Opinion on Investigational Drugs</i> , 2019 , 28, 573-581	5.9	19
63	Predictors of response to anti-TNF therapy in RA patients with moderate or high DAS28'scores. <i>Joint Bone Spine</i> , 2014 , 81, 37-40	2.9	19
62	Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. <i>BioMed Research International</i> , 2014 , 2014, 831603	3	18
61	Prevalence of COVID infections in a population of rheumatic patients from Lombardy and Marche treated with biological drugs or small molecules: A multicentre retrospective study. <i>Journal of Autoimmunity</i> , 2021 , 116, 102545	15.5	18
60	Switch or swap strategy in rheumatoid arthritis patients failing TNF inhibitors? Results of a modified Italian Expert Consensus. <i>Rheumatology</i> , 2018 , 57, vii42-vii53	3.9	18
59	Factors influencing the choice of first- and second-line biologic therapy for the treatment of rheumatoid arthritis: real-life data from the Italian LORHEN Registry. <i>Clinical Rheumatology</i> , 2017 , 36, 753-761	3.9	17
58	Two-year persistence of golimumab as second-line biologic agent in rheumatoid arthritis as compared to other subcutaneous tumor necrosis factor inhibitors: real-life data from the LORHEN registry. <i>International Journal of Rheumatic Diseases</i> , 2018 , 21, 422-430	2.3	17

57	Does polymorphism of genes coding for pro-inflammatory mediators predict the clinical response to tnf alpha blocking agents? A review analysis of the literature. <i>Autoimmunity Reviews</i> , 2011 , 10, 460-3	13.6	17
56	Impact of corticosteroids and immunosuppressive therapies on symptomatic SARS-CoV-2 infection in a large cohort of patients with chronic inflammatory arthritis. <i>Arthritis Research and Therapy</i> , 2020 , 22, 290	5.7	17
55	Two-year retention rate of golimumab in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis: data from the LORHEN registry. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 804-809	2.2	17
54	Persistence, switch rates, drug consumption and costs of biological treatment of rheumatoid arthritis: an observational study in Italy. <i>ClinicoEconomics and Outcomes Research</i> , 2017 , 9, 9-17	1.7	16
53	Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: results from the GISEA register. <i>Joint Bone Spine</i> , 2014 , 81, 508-12	2.9	15
52	Drug survival of adalimumab in patients with rheumatoid arthritis over 10 years in the real-world settings: high rate remission together with normal function ability. <i>Clinical Rheumatology</i> , 2016 , 35, 2649-2656	3.9	14
51	Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 211-223	4.4	14
50	Role of antimalarials in COVID-19: observational data from a cohort of rheumatic patients. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, e75	2.4	13
49	The Giants (biologics) against the Pigmies (small molecules), pros and cons of two different approaches to the disease modifying treatment in rheumatoid arthritis. <i>Autoimmunity Reviews</i> , 2020 , 19, 102421	13.6	12
48	Secukinumab efficacy in patients with PsA is not dependent on patientsRbody mass index. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	11
47	Incidence of cancer in patients with spondyloarthritis treated with anti-TNF drugs. <i>Joint Bone Spine</i> , 2018 , 85, 455-459	2.9	11
46	The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry. <i>Journal of International Medical Research</i> , 2016 , 44, 113-118	1.4	11
45	Psoriasis and psoriatic arthritis: How to manage immunosuppressants in COVID-19 days. <i>Dermatologic Therapy</i> , 2020 , 33, e13415	2.2	10
44	The role of concomitant methotrexate dosage and maintenance over time in the therapy of rheumatoid arthritis patients treated with adalimumab or etanercept: retrospective analysis of a local registry. <i>Drug Design, Development and Therapy</i> , 2018 , 12, 1421-1429	4.4	10
43	Clinical evaluation of a novel chemiluminescent immunoassay for the detection of anti-citrullinated peptide antibodies. <i>Clinica Chimica Acta</i> , 2014 , 437, 161-7	6.2	10
42	A review of the literature analyzing benefits and concerns of infliximab biosimilar CT-P13 for the treatment of rheumatologic diseases: focus on interchangeability. <i>Drug Design, Development and Therapy</i> , 2017 , 11, 1969-1978	4.4	10
41	Ultrasonography in the diagnosis and management of patients with inflammatory arthritides. <i>European Journal of Internal Medicine</i> , 2014 , 25, 103-11	3.9	10
40	The Use of Rheumatic Disease Comorbidity Index for Predicting Clinical Response and Retention Rate in a Cohort of Rheumatoid Arthritis Patients Receiving Tumor Necrosis Factor Alpha Inhibitors. <i>BioMed Research International</i> , 2019 , 2019, 6107217	3	10

39	The role of biologic agents in damage progression in rheumatoid arthritis: indirect comparison of data coming from randomized clinical trials. <i>Therapeutic Advances in Musculoskeletal Disease</i> , 2012 , 4, 213-23	3.8	9
38	The Management of Acute Anterior Uveitis Complicating Spondyloarthritis: Present and Future. <i>BioMed Research International</i> , 2018 , 2018, 9460187	3	9
37	Is there a need for new thresholds to define remission and low disease activity by Disease Activity Score 28 calculated with C reactive protein? Real life data from a local registry. <i>Annals of the Rheumatic Diseases</i> , 2015 , 74, e5	2.4	8
36	Personalized medicine in rheumatoid arthritis: How immunogenicity impacts use of TNF inhibitors. <i>Autoimmunity Reviews</i> , 2020 , 19, 102509	13.6	8
35	The comparison of effects of biologic agents on rheumatoid arthritis damage progression is biased by period of enrollment: data from a systematic review and meta-analysis. <i>Seminars in Arthritis and Rheumatism</i> , 2014 , 43, 730-7	5.3	8
34	Prevalence of Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease in a cohort of patients treated with TNF-alpha inhibitors. <i>Modern Rheumatology</i> , 2018 , 28, 542-549	3.3	7
33	Structural integrity versus radiographic progression in rheumatoid arthritis. <i>RMD Open</i> , 2015 , 1, e000064	5.9	7
32	Effects of anti-TNF alpha drugs on disability in patients with rheumatoid arthritis: long-term real-life data from the Lorhen Registry. <i>BioMed Research International</i> , 2014 , 2014, 416892	3	7
31	The Expanded Risk Score in Rheumatoid Arthritis (ERS-RA): performance of a disease-specific calculator in comparison with the traditional prediction scores in the assessment of the 10-year risk of cardiovascular disease in patients with rheumatoid arthritis. <i>Swiss Medical Weekly</i> , 2018 , 148, w14656	3.1	7
30	Sarilumab: patient-reported outcomes in rheumatoid arthritis. <i>Patient Related Outcome Measures</i> , 2018 , 9, 275-284	2.9	7
29	Tofacitinib's infectious profile: concerns for clinical practice. <i>Lancet Rheumatology, The</i> , 2020 , 2, e65-e67	14.2	6
28	Biologic discontinuation strategies and outcomes in patients with rheumatoid arthritis. <i>Expert Review of Clinical Immunology</i> , 2019 , 15, 1313-1322	5.1	6
27	Low frequency of disease flare in patients with rheumatic musculoskeletal diseases who received SARS-CoV-2 mRNA vaccine.. <i>Arthritis Research and Therapy</i> , 2022 , 24, 21	5.7	6
26	Considerations for improving quality of care of patients with rheumatoid arthritis and associated comorbidities. <i>RMD Open</i> , 2020 , 6,	5.9	5
25	GM-CSF in the treatment of COVID-19: a new conductor in the pathogenesis of cytokine storm?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e448-e449	14.2	5
24	Golimumab effectiveness in biologic inadequate responding patients with rheumatoid arthritis, psoriatic arthritis and spondyloarthritis in real-life from the Italian registry GISEA. <i>Joint Bone Spine</i> , 2021 , 88, 105062	2.9	5
23	Comparison of efficacy of first- versus second-line adalimumab in patients with rheumatoid arthritis: experience of the Italian biologics registries. <i>Clinical and Experimental Rheumatology</i> , 2017 , 35, 660-665	2.2	5
22	Increasing the threshold for patient global assessment in defining remission may have a different impact in patients with early and established rheumatoid arthritis. <i>Annals of the Rheumatic Diseases</i> , 2020 ,	2.4	4

21	Dr. Favalli, reply. <i>Journal of Rheumatology</i> , 2020 , 47, 1592	4.1	4
20	Managing patients with rheumatic conditions during the covid-19 pandemic. <i>BMJ, The</i> , 2020 , 369, m16335.9	3.9	4
19	Ensuring tight control in patients with rheumatoid arthritis treated with targeted therapies during the COVID-19 pandemic using a telehealth strategy. <i>Annals of the Rheumatic Diseases</i> , 2021 , 80, 1243-1244	2.4	4
18	Real-world 6 and 12-month Drug Retention, Remission and Response Rates of Secukinumab in 2,017 Psoriatic Arthritis patients in 13 European Countries. <i>Arthritis Care and Research</i> , 2021 ,	4.7	4
17	Change Over Time in the Pattern of Clinical Response to First-line Biologic Drugs in Patients with Rheumatoid Arthritis: Observational Data in a Real-life Setting. <i>Journal of Rheumatology</i> , 2017 , 44, 262-263	4.1	3
16	Vitamin D and Spondyloarthritis: Review of the Literature. <i>Open Rheumatology Journal</i> , 2018 , 12, 214-225.2	2	3
15	Clinical management of patients with rheumatoid arthritis during the COVID-19 pandemic. <i>Expert Review of Clinical Immunology</i> , 2021 , 17, 561-571	5.1	3
14	Efficacy and retention rate of adalimumab in rheumatoid arthritis and psoriatic arthritis patients after first-line etanercept failure: the FEARLESS cohort. <i>Rheumatology International</i> , 2020 , 40, 263-272	3.6	3
13	Retrospective evaluation of patient profiling and effectiveness of apremilast in an Italian multicentric cohort of psoriatic arthritis patients. <i>Clinical and Experimental Rheumatology</i> , 2020 , 38, 19-26.2	2.2	3
12	Tocilizumab after a first-line with anti-TNF in rheumatoid arthritis: a cost-consequence analysis in the Italian setting. <i>Clinical and Experimental Rheumatology</i> , 2018 , 36, 479-485	2.2	2
11	Comments on "Short-term reasons for withdrawal and adverse events associated with apremilast therapy for psoriasis in real-world practice compared with in clinical trials: A multicenter retrospective study". <i>Journal of the American Academy of Dermatology</i> , 2018 , 79, e119-e120	4.5	1
10	Clinical pharmacology of filgotinib in the treatment of rheumatoid arthritis: current insights. <i>Expert Review of Clinical Pharmacology</i> , 2021 , 14, 661-670	3.8	1
9	SAT0375 MILD COGNITIVE IMPAIRMENT IN PSORIATIC ARTHRITIS: PREVALENCE AND ASSOCIATED FACTORS 2019 ,		1
8	The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts. <i>Autoimmunity Reviews</i> , 2018 , 17, 1251-1258	13.6	1
7	Is there really room for anti-rheumatic drugs in the treatment of COVID-19?. <i>Scandinavian Journal of Rheumatology</i> , 2020 , 49, 412-413	1.9	0
6	Factors Predicting Early Failure of Etanercept in Rheumatoid Arthritis: An Analysis From the Gruppo Italiano di Studio sulla Early Arthritis (Italian Group for the Study of Early Arthritis) Registry. <i>Archives of Rheumatology</i> , 2020 , 35, 163-169	0.9	0
5	Secukinumab in HLA-B27 associated uveitis. <i>Clinical and Experimental Ophthalmology</i> , 2021 , 49, 388-389	2.4	0
4	An Italian Disease-Based Registry of Axial and Peripheral Spondyloarthritis: The SIRENA Study. <i>Frontiers in Medicine</i> , 2021 , 8, 711875	4.9	0

3	The Impact of Anti-rheumatic Drugs on the Seroprevalence of Anti-SARS-CoV-2 Antibodies in a Cohort of Patients With Inflammatory Arthritis: The MAINSTREAM Study.. <i>Frontiers in Medicine</i> , 2022 , 9, 850858	4.9	o
2	Prédicteurs de la réponse aux traitements anti-TNF chez les patients ayant une polyarthrite rhumatoïde avec des scores DAS28 modifiés ou élevés. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2014 , 81, 54-57	0.1	
1	Incidence du cancer chez les patients atteints de spondyloarthrite traités par anti-TNF. <i>Revue Du Rhumatisme (Edition Francaise)</i> , 2019 , 86, 75-80	0.1	